Agreement Provides rHA Source to Japan and China

Recombinant human albumin (rHA) developer Albumex Ltd, has announced a distribution agreement with reagent supplier FUJIFILM Wako Pure Chemical Corporation (FUJIFILM Wako) in Japan and China including Hong Kong.

"With this partnership, Albumedix gains a valued and experienced partner with an established presence in Japan and China. FUJIFILM Wako is highly experienced in the advanced therapy and biopharmaceutical space, where Albumedix products have proven to be vital enablers. We look forward to a strong collaboration with FUJIFILM Wako in order to enable the continued development of transformative therapies in the region," said Gregor Kawaletz, Chief Commercial Officer at Albumedix.   

"Albumedix' products are an integral part of the processing and formulation of advanced therapies and biopharmaceuticals such as vaccines, cell and gene therapies. The high quality and purity along with extensive regulatory documentation and expert support will offer a versatile tool for the customers of FUJIFILM Wako. FUJIFILM Wako will be working through well-established sales channels and mature network of dealers and local representatives, relying on local language and dedicated specialists to broaden the use of Albumedix products and enable the development of therapies and biopharmaceuticals in the respective territories," said Mr. Kuniaki Okamoto, General Manager, Life Science Development Operations.

More information online